Sun Pharma launches COVID-19 treatment drug FluGuard® in India at Rs. 35 per tablet

Mumbai : Indian pharmaceuticals company Sun Pharmaceutical Industries Limited on Tuesday announced the launch of COVID-19 treatment drug FluGuard® (Favipiravir 200 mg) at Rs. 35 per tablet in the country.

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

“With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard® at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response” Kirti Ganorkar, CEO of India Business, Sun Pharma said.

The company has said that it will work closely with the government and medical community to ensure availability of FluGuard® to patients across the country. The stocks of FluGuard® will be available in the market from this week.